Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011817:Rabbits
D000970:Antineoplastic Agents; C016163:valrubicin; D004317:Doxorubicin